Untitled

Georgiadis, A.; Papavasiliou, Eleni C.; Lourida, E.; Alamanos, Yannis; Kostara, Christina; Tselepis, Alexandros D.; Drosos, Alexandros A.

doi:10.1186/ar1952

Cited by 208 publications

(49 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the RA activity (DAS) was significantly high among RA patients with dyslipidemia (p=0.02). This is consistent with results of Georgiadis et al study in Greece 50 .…”

Section: Resultssupporting

confidence: 83%

Prevalence of Dyslipidemia and Its Association With Disease Activity in Patients With Rheumatoid Arthritis in Sulaimani Governorate

Gharib

2016

UJPR

View full text Add to dashboard Cite

Rheumatoid arthritis is a systemic inflammatory disease characterized by chronic and erosive polyarthritis it is the most common inflammatory arthritis, affecting from 0.5-1% of the general population. Dyslipidemia is a quite important problem in Rheumatoid arthritis (RA) patient, which causes morbidity and mortality. As known, dyslipidemia is one of atherosclerosis risk-factor, and main mortality cause of longstanding RA patient. Objectives are to measure prevalence of dyslipidemia in patients with Rheumatoid Arthritis compared with healthy control peoples and to find out correlations between dyslipidemia and disease activity in patients with Rheumatoid Arthritis. A total of one hundred patients with RA (80 female and 20 male) were included in the study, they were attending consultation clinic and division of rheumatology in the General Medical Teaching Hospital in Slemani city from (October 2015 to September 2016) who fulfilling the 2010 American College of Rheumatology/European league against Rheumatism classification criteria for RA and one hundred healthy age and sex-matched controls. Fasting lipid profiles of cases and control were estimated after an overnight fast of 12 hours. Association between lipid profile and disease activity using disease activity score DAS 28, inflammatory markers (CRP and ESR) was also determined. RA patients showed a higher prevalence of associated dyslipidemia (48%) in comparison to control (4%) p-value less than 0.001.Our result showed a significant reduction in serum high density lipoproteins (HDL) p-value less than 0.001, with significant elevation of serum total cholesterol, triglyceride, low density lipoprotein and very low density lipoprotein p-value 0.001, 0.007, 0.01and 0.5 respectively in comparison to controls. There is a significant association between dyslipidemia and high DAS 28 score (p=0.02). There is a significant association between high ESR of RA patients and dyslipidemia (p=0.001). A significant association was observed between high CRP level and RA patients with no dyslipidemia (p<0.001). Dyslipidemia are frequent among the patients with rheumatoid arthritis and highly associated with active RA. Serum HDL significantly reduced while other parameters of lipid profiles significantly increased in comparisons to control.

show abstract

“…In our study, the RA activity (DAS) was significantly high among RA patients with dyslipidemia (p=0.02). This is consistent with results of Georgiadis et al study in Greece 50 .…”

Section: Resultssupporting

confidence: 83%

Prevalence of Dyslipidemia and Its Association With Disease Activity in Patients With Rheumatoid Arthritis in Sulaimani Governorate

Gharib

2016

UJPR

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis found that methotrexate use was associated with 21% fewer CV events (Figure 1)(40). Methotrexate does not appear to alter lipid profiles (41), and there is insufficient evidence about its effects on insulin resistance, hypertension or atherosclerotic plaque burden. Nevertheless, the apparent benefit of methotrexate in reducing heart disease risk in RA, and the strong evidence that CRP is a risk factor for heart disease, led to the development of a large randomized trial (http://ClinicalTrials.gov identifier: NCT01594333) designed to determine whether low dose methotrexate reduces heart disease risk in post-MI patients who have metabolic syndrome or diabetes mellitus (42).…”

Section: Effect Of Ra Therapies On CV Risk In Ramentioning

confidence: 99%

Rheumatoid arthritis and cardiovascular disease

Crowson

Liao

Davis

et al. 2013

American Heart Journal

273

185

View full text Add to dashboard Cite

Background Rheumatic disease and heart disease share common underpinnings involving inflammation. The high levels of inflammation that characterize rheumatic diseases provide a “natural experiment” to help elucidate the mechanisms by which inflammation accelerates heart disease. Rheumatoid arthritis (RA) is the most common of the rheumatic diseases and has the best studied relationships with heart disease. Methods Review of current literature on heart disease and rheumatoid arthritis Results Patients with RA have an increased risk of developing heart disease that is not fully explained by traditional cardiovascular risk factors. Therapies used to treat RA may also affect the development of heart disease; by suppressing inflammation, they may also reduce the risk of heart disease. However, their other effects, as in the case of steroids, may increase heart disease risk. Conclusions Investigations of the innate and adaptive immune responses occurring in RA may delineate novel mechanisms in the pathogenesis of heart disease, and help identify novel therapeutic targets for the prevention and treatment of heart disease.

show abstract

“…Research over the past decade has demonstrated increased CV risk in patients with rheumatoid arthritis (RA) versus non-RA subjects (5–7). However, the association between lipid levels and CV risk in RA appears to be more complex than in the general population, with systemic inflammation being a potential important contributor to changes in lipid profile (8).…”

Section: Introductionmentioning

confidence: 99%

Use of Lipid-lowering Agents in Rheumatoid Arthritis: A Population-based Cohort Study

Veetil

Myasoedova

Matteson³

et al. 2013

J Rheumatol

View full text Add to dashboard Cite

Objective Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease and mortality. Lipid-lowering therapy is reportedly underused in patients with RA. However, longitudinal cohort studies comparing the use of lipid-lowering medications in patients with RA vs the general population are lacking. Methods Cardiovascular risk factors, lipid measures and use of lipid-lowering agents were assessed in a population-based inception cohort of patients with RA and a cohort of non-RA subjects followed from 1/1/1988 to 12/31/2008. The National Cholesterol Education Program (NCEP) adult treatment panel III (ATP III) guidelines were assessed at the time of each lipid measure throughout follow-up. Time from meeting guidelines to initiation of lipid-lowering agents was assessed using Kaplan-Meier methods. Results The study population included 412 RA and 438 non-RA patients with ≥1 lipid measure during follow-up and no prior use of lipid lowering agents. Rates of lipid testing were lower among patients with RA compared to non-RA subjects. Among patients who met NCEP ATP III criteria for lipid-lowering therapy (n=106 RA and n=120 non-RA), only 27% of RA and 26% of non-RA subjects initiated lipid-lowering agents within 2 years of meeting guidelines for initiation. Conclusions There was substantial undertreatment in both the RA and non-RA cohorts who met NCEP ATP III criteria for initiation of lipid-lowering agents. Patients with RA did not have as frequent lipid testing as individuals in the general population.

show abstract

Untitled

Cited by 208 publications

References 43 publications

Prevalence of Dyslipidemia and Its Association With Disease Activity in Patients With Rheumatoid Arthritis in Sulaimani Governorate

Prevalence of Dyslipidemia and Its Association With Disease Activity in Patients With Rheumatoid Arthritis in Sulaimani Governorate

Rheumatoid arthritis and cardiovascular disease

Use of Lipid-lowering Agents in Rheumatoid Arthritis: A Population-based Cohort Study

Contact Info

Product

Resources

About